1. Introduction

Cross-Border Recognition of Electronic Prescriptions refers to the legal recognition, verification, acceptance and dispensing of an electronic medical prescription issued by a doctor in one country when a patient seeks to obtain the prescribed medicine in another country.

For example:

An Indian doctor issues an electronic prescription to a patient travelling to Germany.

A British doctor electronically prescribes medicine to a patient residing in India.

A patient receives an e-prescription in France and seeks to purchase the medicine in Spain.

A patient undergoing cancer treatment in Japan seeks to obtain the same prescribed medicine while temporarily residing in Australia.

These situations create complex legal questions concerning medical licensing, pharmaceutical regulation, electronic signatures, patient identification, prescription authentication, data protection and cross-border healthcare.

The central legal question is:

Must a pharmacy in one country accept an electronic prescription issued by a doctor legally authorised to practise in another country?

The answer is not universally affirmative. Recognition depends on applicable international arrangements, domestic legislation, professional licensing requirements, medicine-approval rules and the dispensing country's public-health safeguards.

The European Union has developed a relatively advanced recognition framework. India, by comparison, has established telemedicine and electronic-record rules but does not have a general system automatically recognising foreign electronic prescriptions.

2. Meaning and legal nature of electronic prescriptions

An electronic prescription (e-prescription) is a medical instruction generated, authenticated, transmitted and stored electronically by an authorised healthcare professional.

It normally contains:

Patient's name and identification details.

Date of birth.

Doctor's name and professional registration.

Medical qualification and licensing information.

Medicine's generic or international non-proprietary name.

Strength and pharmaceutical formulation.

Quantity and dosage.

Duration of treatment.

Date of issue.

Electronic signature or other recognised authentication.

Prescription reference number.

Relevant clinical instructions.

An electronic prescription is not merely a digital document. It represents the exercise of professional medical authority.

Its legal validity therefore involves three separate questions:

Document validity: Is the electronic document legally authentic?

Professional validity: Was it issued by a person legally authorised to prescribe?

Dispensing validity: Can the pharmacy lawfully supply the medicine under the law of its jurisdiction?

A prescription can satisfy the first requirement without satisfying the other two.

3. Objectives of cross-border recognition

Cross-border recognition serves several important purposes.

A. Continuity of medical treatment

Patients travelling internationally should not unnecessarily interrupt treatment because their prescriptions were issued in another country.

B. International patient mobility

Recognition supports medical tourism, international employment, education and temporary residence abroad.

C. Reduction of administrative barriers

Electronic recognition can eliminate repeated medical consultations and unnecessary paper documentation.

D. Patient safety

Standardised prescription information helps pharmacists identify medicines, dosages, contraindications and prescribing professionals.

E. Prevention of prescription fraud

Electronic authentication and verification systems help detect forged prescriptions, duplicate prescriptions and unauthorised prescribing.

F. International healthcare cooperation

Recognition facilitates cooperation between hospitals, pharmacies, doctors, insurers and healthcare regulators.

4. International legal framework

A. EU Directive 2011/24/EU

The most important international-regional legal framework is Directive 2011/24/EU on the application of patients' rights in cross-border healthcare.

Article 11 establishes the principle of recognition of prescriptions issued in another EU Member State.

Under Article 11(1):

Member States must ensure recognition of qualifying prescriptions issued in another Member State.

Recognition applies to medicines authorised for marketing in the dispensing country.

Restrictions must be necessary and proportionate to protect human health, non-discriminatory, or based on legitimate doubts concerning authenticity, content or comprehensibility.

National dispensing rules continue to apply.

Recognition does not automatically guarantee reimbursement.

This provision establishes an important distinction between recognising the prescription and requiring a pharmacy to dispense a medicine contrary to its domestic law.

EUR-Lex+1

B. Commission Implementing Directive 2012/52/EU

This Directive establishes minimum information requirements to facilitate recognition of prescriptions issued in another Member State.

The prescribed information includes:

The purpose is to enable pharmacists to verify the prescriber's authority and understand the prescription.

It also favours the use of international non-proprietary names rather than brand names, subject to specified exceptions.

EUR-Lex+1

C. EU electronic prescription interoperability

The EU has developed cross-border digital health infrastructure through which participating Member States can exchange electronic prescription and dispensing information.

However, legal recognition and technical interoperability are different matters.

A prescription might be legally recognised but technically inaccessible through the dispensing country's electronic system.

Conversely, an electronically transmitted document might be technically accessible but fail the legal requirements for dispensing.

The European Commission's ePrescription and eDispensation guidelines, including Release 3.1, published in 2024, provide further technical guidance on electronic exchange.

Public Health+1

D. International data protection framework

Cross-border prescription systems involve sensitive medical information.

Relevant legal protections include:

EU General Data Protection Regulation (GDPR).

Convention 108+ of the Council of Europe.

Domestic health-data protection legislation.

Contractual and cybersecurity obligations imposed on digital healthcare providers.

Under the GDPR, health information is a special category of personal data under Article 9.

Its processing requires an applicable legal basis and compliance with relevant safeguards.

Cross-border electronic prescription systems must therefore consider lawful processing, data minimisation, security, access controls and international transfers.

5. Legal position in India

India is particularly important because it has a growing digital healthcare and online pharmacy sector.

There is no general Indian statutory mechanism that automatically recognises an electronic prescription issued by a doctor licensed exclusively in a foreign country.

Several existing laws and regulatory instruments nevertheless govern relevant aspects of the issue.

A. Information Technology Act, 2000

The Information Technology Act, 2000 provides the legal foundation for electronic records and electronic authentication.

Important provisions include:

Section 4 – Legal recognition of electronic records

Electronic records cannot be denied legal recognition merely because they are in electronic form, provided the statutory requirements are satisfied.

Section 5 – Legal recognition of electronic signatures

Electronic signatures can receive legal recognition where the requirements of the Act are fulfilled.

Section 10A – Validity of contracts formed through electronic means

Contracts are not unenforceable merely because electronic means were used in their formation.

However, these provisions do not independently authorise a foreign doctor to practise medicine in India or compel an Indian pharmacist to dispense a foreign prescription.

B. Telemedicine Practice Guidelines, 2020

The Ministry of Health and Family Welfare issued the Telemedicine Practice Guidelines on 25 March 2020.

These guidelines were incorporated into the Indian Medical Council professional-conduct framework.

They regulate important aspects of electronic medical consultations and prescribing.

The principal requirements include:

Identification of the doctor and patient.

Verification of professional credentials.

Appropriate patient consent.

Selection of an appropriate communication method.

Adequate patient evaluation.

Appropriate diagnosis or provisional diagnosis.

Compliance with prescription restrictions.

Maintenance of medical records.

Patient confidentiality.

Professional accountability.

The guidelines recognise telemedicine as a legitimate mode of healthcare delivery when properly conducted.

However, they do not establish a comprehensive cross-border prescription-recognition arrangement between India and foreign countries.

A crucial issue is that the guidelines are framed around Registered Medical Practitioners authorised under the Indian medical registration framework. They should not be interpreted as automatically authorising every foreign doctor to prescribe medicines for patients located in India.

Ministry of Health and Family Welfare+2

C. Drugs and Cosmetics Act, 1940 and Drugs Rules, 1945

The Drugs and Cosmetics Act, 1940 and Drugs Rules, 1945 govern the manufacture, import, sale and distribution of medicines.

Important regulatory considerations include:

Whether the medicine is authorised for sale in India.

Whether it belongs to Schedule H, H1 or X.

Whether the dispensing pharmacy holds the appropriate licence.

Whether the prescription meets applicable requirements.

Whether repeat dispensing is permitted.

Whether the medicine is subject to additional restrictions.

For example, a medicine lawfully prescribed in the United States may not necessarily be lawfully dispensed in India.

A foreign electronic prescription cannot override Indian restrictions on the sale or distribution of pharmaceutical products.

The Central Drugs Standard Control Organisation (CDSCO) provides access to the Drugs Rules and related regulatory notifications.

CDSCO+1

D. Narcotic Drugs and Psychotropic Substances Act, 1985

The Narcotic Drugs and Psychotropic Substances Act, 1985 creates additional restrictions concerning narcotic drugs and psychotropic substances.

Foreign electronic prescriptions cannot automatically authorise dispensing of controlled medicines in India.

The relevant questions include:

Is the substance legally permitted?

Is the prescribing professional authorised?

Is the purpose medically legitimate?

Are the statutory prescription and recordkeeping requirements satisfied?

Are import, possession and dispensing restrictions complied with?

This area requires particular caution because a prescription valid in the issuing country may be legally insufficient in India.

E. Digital Personal Data Protection Act, 2023

The Digital Personal Data Protection Act, 2023 is relevant to the processing of personal digital information.

Cross-border electronic prescriptions may involve disclosure of patient identification, medical history, treatment details and prescription records.

Healthcare platforms must examine the applicable provisions governing lawful processing, security and international data transfers, together with relevant rules and commencement notifications.

It is important not to assume that electronic transmission automatically makes the underlying medical information available for unrestricted international sharing.

6. Important judicial decisions and case laws

There is an important distinction between judgments directly concerning cross-border prescription recognition and judgments dealing with the legal validity of remote prescribing.

The following cases are particularly relevant.

Case 1. VIPA Kereskedelmi és Szolgáltató Kft. v. Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet

Directly relevant cross-border prescription case

Court: Court of Justice of the European Union

Citation: Case C-222/18, ECLI:EU:C:2019:751

Date: 18 September 2019.

Facts:

VIPA operated a pharmacy in Hungary.

The pharmacy dispensed prescription-only medicines on the basis of order forms issued by healthcare professionals operating in other Member States.

The Hungarian regulatory authority objected because the documents did not identify the patients for whom the medicines were intended.

The dispute concerned the interpretation of Article 11 of Directive 2011/24/EU.

Legal issues:

Whether foreign healthcare professionals' order forms qualified as prescriptions.

Whether a prescription without patient identification had to be recognised.

Whether Hungary could restrict dispensing on public-health grounds.

Judgment:

The CJEU held that the recognition obligation under Article 11(1) did not extend to order forms that failed to identify the patient concerned.

The Court considered the requirements of Directive 2012/52/EU and the objective of protecting patients through reliable prescription information.

Legal principles established:

Cross-border recognition is not unconditional.

Patient identification is an important legal requirement.

Foreign professional authorisation does not eliminate dispensing safeguards.

Public-health restrictions can be justified when proportionate.

Importance:

This is one of the most significant judgments for cross-border prescription recognition.

It establishes that international prescription recognition must be accompanied by adequate patient identification and authentication.

EUR-Lex+2

Case 2. Deepa Sanjeev Pawaskar & Anr. v. State of Maharashtra

Court: Bombay High Court

Citation: 2018 SCC OnLine Bom 1841.

Date: 25 July 2018.

Facts:

The case concerned doctors who allegedly gave treatment instructions over the telephone without adequately examining or assessing a patient.

The patient was subsequently administered medicines and died.

The doctors sought anticipatory bail.

Legal issue:

Whether prescribing treatment remotely without sufficient medical assessment could constitute criminal negligence.

Judgment:

The Bombay High Court considered the alleged absence of proper medical inquiry and the administration of medicines without adequate diagnosis.

The Court treated the allegations as serious and declined anticipatory bail.

Legal principles:

Remote prescribing does not remove the doctor's professional responsibility.

A prescription should be supported by adequate medical evaluation.

Telephonic instructions cannot be used to avoid professional standards.

Serious negligence may attract criminal consequences.

Relevance to cross-border electronic prescriptions:

A foreign electronic prescription must be assessed not merely for its digital authenticity but also for the adequacy of the underlying medical consultation.

A valid electronic signature cannot cure an unsafe or negligent prescribing process.

NearLaw+1

Case 3. Priyanka Singh & Anr. v. State of Maharashtra & Ors.

Court: Bombay High Court.

Date: 15 February 2021.

Facts:

The proceedings arose from allegations involving electronic prescriptions for medicines regulated under the NDPS Act.

The case concerned the prescription of controlled medicines and the application of the Telemedicine Practice Guidelines.

Legal issues:

Whether the prescribing process complied with telemedicine requirements.

Whether patient identity and consent had been properly verified.

Whether the prescribed medicines fell within restricted categories.

Whether the allegations justified criminal investigation.

Judicial reasoning:

The Court examined the Telemedicine Practice Guidelines, including requirements relating to patient identification, consent, appropriate diagnosis and restricted medicines.

The Court emphasised that medicines cannot be prescribed through telemedicine without adequate medical information and compliance with prescribing restrictions.

Legal significance:

The case illustrates that electronic prescription validity depends on compliance with substantive pharmaceutical and professional rules.

A foreign electronic prescription cannot be treated as automatically valid simply because it originates from an established digital healthcare platform.

Important qualification: This was not a judgment establishing a general international recognition rule. Its relevance is to remote prescribing and controlled-medicine safeguards.

Indian Kanoon+1

Case 4. Jacob Mathew v. State of Punjab

Court: Supreme Court of India.

Citation: (2005) 6 SCC 1.

Facts:

The case concerned allegations of criminal medical negligence against a medical professional.

Legal issue:

What standard should apply before criminal liability is imposed on a doctor for medical negligence?

Judgment:

The Supreme Court explained the distinction between ordinary negligence and criminal negligence.

Criminal liability requires a sufficiently high degree of negligence, rather than merely an error of judgment or a simple lapse.

Relevance:

In cross-border electronic prescribing disputes, a doctor may face questions about the adequacy of remote assessment, the patient's medical history and the decision to prescribe a particular medicine.

The principles in Jacob Mathew are relevant when determining whether the alleged conduct reaches the threshold of criminal medical negligence.

This judgment does not itself decide the recognition of foreign electronic prescriptions.

Case 5. Indian Medical Association v. V.P. Shantha

Court: Supreme Court of India.

Citation: (1995) 6 SCC 651.

Facts:

The dispute concerned the application of consumer-protection law to medical services.

Legal issue:

Whether medical services could fall within the definition of services under consumer-protection legislation.

Judgment:

The Supreme Court established that medical services could fall within consumer-protection jurisdiction, subject to the distinctions explained in the judgment.

Relevance:

Electronic prescription platforms, healthcare providers and pharmacies may face consumer claims where deficient services cause injury or financial loss.

For example:

A platform authenticates a fraudulent prescription.

A pharmacy dispenses the wrong medicine.

A telemedicine provider fails to verify the patient's medical information.

A digital healthcare service improperly transmits prescription information.

The judgment supplies a consumer-law foundation for examining such disputes, although it does not directly govern international recognition.

7. Comparative legal position in different countries

A. European Union

The EU has the most developed regional framework for cross-border prescription recognition.

Its system is based on:

Directive 2011/24/EU.

Implementing Directive 2012/52/EU.

National pharmaceutical legislation.

Cross-border eHealth interoperability arrangements.

A prescription issued in one Member State can generally be presented in another Member State, subject to the applicable requirements.

However, not every national electronic prescription system is interoperable. Patients may still need a paper copy.

Furthermore, the dispensing pharmacy must follow the laws of the country where it operates.

Your Europe+1

B. United States

The United States follows a combination of federal and state regulation.

Important federal legislation includes the Controlled Substances Act and its implementing regulations.

Under 21 CFR Part 1311, electronic prescriptions for controlled substances must satisfy prescribed security, authentication and software requirements.

The Drug Enforcement Administration (DEA) regulates electronic prescriptions for controlled substances.

A distinction must be made between interstate and international prescriptions.

The DEA explains that federal law does not automatically prohibit a pharmacist from filling a controlled-substance prescription issued by a practitioner registered in another state. Nevertheless, state laws may impose additional restrictions.

This interstate principle should not be confused with automatic recognition of prescriptions from foreign countries.

Prescriptions Q&A+2

C. United Kingdom

The UK has its own regulatory framework for medical prescribing and pharmaceutical dispensing.

Important institutions include:

General Medical Council (GMC).

General Pharmaceutical Council (GPhC).

Medicines and Healthcare products Regulatory Agency (MHRA).

National Health Service (NHS).

A prescription issued abroad is not automatically equivalent to a UK prescription for every medicine.

The receiving pharmacist must consider the prescriber's professional authority, the prescription's authenticity, the medicine's legal classification and applicable UK dispensing requirements.

D. Australia

Australia regulates prescribing through federal and state or territory legislation.

Important institutions include:

Australian Health Practitioner Regulation Agency (Ahpra).

Medical Board of Australia.

Therapeutic Goods Administration (TGA).

State and territory pharmacy regulators.

Foreign prescriptions must be assessed against Australian requirements concerning prescribing authority, medicine scheduling and lawful dispensing.

E. Japan

Japan regulates pharmaceutical products through its domestic pharmaceutical and medical-practice framework.

Foreign electronic prescriptions do not automatically acquire domestic legal validity simply because they have been issued by a recognised overseas hospital.

Relevant questions include:

Whether the prescribing professional is authorised under the applicable rules.

Whether the medicine is approved or lawfully available.

Whether the prescription meets domestic requirements.

Whether importation or personal-use restrictions apply.

8. Major legal challenges

A. Conflict of medical licensing laws

This is one of the most difficult issues.

Suppose a doctor is registered in France but prescribes medication electronically to a patient located in India.

Questions arise:

Is the doctor authorised to provide medical services to a patient located in India?

Does Indian law recognise the doctor's foreign qualification?

Does the prescription constitute practising medicine in India?

Can the patient obtain the prescribed medicine from an Indian pharmacy?

The legal recognition of the foreign doctor's professional status and the legal recognition of the prescription are separate questions.

B. Electronic signature authentication

A major difficulty is determining whether a foreign electronic signature is legally acceptable in the receiving country.

Possible verification methods include:

Digital certificates.

Public Key Infrastructure (PKI).

Qualified electronic signatures.

Healthcare-provider registration databases.

Cryptographic verification.

Secure prescription identifiers.

Different countries may recognise different authentication standards.

A prescription digitally signed under one country's legislation may not automatically satisfy the receiving country's electronic-signature requirements.

C. Patient identity fraud

Cross-border electronic prescription systems create opportunities for identity-related offences.

Examples include:

Identity theft.

Use of another person's prescription.

Forged doctor credentials.

Duplicate prescriptions.

Manipulated dosage information.

Fraudulent healthcare accounts.

Legal systems must ensure that prescription verification identifies both the patient and the prescribing professional.

D. Medicine classification differences

The same medicine may have different legal classifications in different countries.

For example, a medicine may be:

Available without prescription in one country.

Prescription-only in another.

Restricted to specialist prescribing in a third.

Prohibited or unauthorised in another jurisdiction.

Consequently, recognition of a prescription cannot override the domestic classification of a medicine.

E. Language and pharmaceutical terminology

A foreign prescription may use a different language, brand name or dosage convention.

This can produce errors in identifying:

Active ingredients.

Concentrations.

Dosage units.

Pharmaceutical formulations.

Administration instructions.

Using international non-proprietary names helps reduce these problems.

F. Controlled medicines and prescription shopping

A patient might attempt to obtain controlled medicines by using different prescriptions in different countries.

This creates risks involving:

Opioid diversion.

Psychotropic medicine misuse.

Duplicate dispensing.

Prescription forgery.

Unlawful importation.

Cross-border trafficking.

International recognition frameworks must therefore provide appropriate verification and monitoring mechanisms.

G. Patient privacy and international data transfers

Electronic prescriptions may contain highly confidential medical information.

Legal questions include:

Which country controls the data?

Where is the prescription stored?

Can a foreign pharmacy access medical history?

Who is responsible for a data breach?

Which country's data protection legislation applies?

Can the information be transferred to another healthcare provider?

The absence of common data-governance standards can undermine international electronic prescription systems.

9. Liability for wrongful recognition or rejection

Cross-border prescription disputes may create liability for several participants.

A. Doctor's liability

A doctor may be responsible for prescribing without adequate patient assessment or for issuing a prescription contrary to applicable restrictions.

B. Pharmacist's liability

A pharmacist must independently comply with the dispensing country's legal requirements.

The pharmacist should not assume that an electronically authenticated prescription is necessarily safe or legally dispensable.

C. Digital platform liability

A digital platform may face liability where its systems fail to verify professional registration, allow prescription manipulation or expose confidential information.

D. Regulatory liability

A regulatory authority's refusal to recognise a foreign prescription may be challenged where the refusal is contrary to an applicable recognition obligation or is arbitrary, discriminatory or disproportionate.

In the EU, Article 11 of Directive 2011/24/EU provides an important legal standard for reviewing such restrictions.

10. Important legal doctrines

Several legal doctrines are particularly relevant to cross-border recognition.

1. Mutual recognition doctrine

A legal act validly performed in one jurisdiction may receive recognition in another under an applicable legal framework.

2. Public health exception

A receiving country may impose proportionate restrictions necessary to protect human health.

3. Territoriality principle

Medical licensing and pharmaceutical dispensing are generally regulated by the jurisdiction in which the relevant professional activity or dispensing takes place.

4. Principle of proportionality

Restrictions on foreign prescriptions should not exceed what is necessary to achieve legitimate regulatory objectives where an applicable recognition obligation exists.

5. Patient autonomy

Patients should receive adequate information concerning their medication and treatment options.

6. Professional accountability doctrine

Electronic communication does not reduce the professional standard of care expected from doctors and pharmacists.

7. Data minimisation principle

Only the patient information necessary for lawful prescription verification and treatment should be exchanged.

11. Hypothetical case studies

Case Study 1: Indian patient with a German electronic prescription

Facts:

An Indian citizen receives a prescription from a doctor in Germany for a medicine used to treat a chronic condition. The patient returns to India and presents the electronic prescription at an Indian pharmacy.

Legal questions:

Is the German doctor authorised to prescribe for the patient under the relevant rules?

Does the electronic document satisfy Indian legal requirements?

Is the medicine authorised for sale in India?

Does it fall under Schedule H, H1 or X?

Can the pharmacist lawfully dispense it?

Legal position:

The German prescription does not automatically become an Indian prescription. The pharmacist must comply with Indian pharmaceutical law and applicable professional requirements.

Case Study 2: French electronic prescription presented in Spain

Facts:

A patient receives an electronic prescription in France and travels to Spain to obtain the medicine.

Legal questions:

Is the prescription issued by an authorised professional?

Does it contain the required patient information?

Can the Spanish pharmacy access the electronic record?

Is the medicine authorised in Spain?

Legal position:

Article 11 of Directive 2011/24/EU and Implementing Directive 2012/52/EU provide the recognition framework.

If the relevant systems are interoperable, the prescription may be retrieved electronically. Otherwise, a paper copy may be necessary.

Case Study 3: Foreign prescription for a controlled substance

Facts:

An overseas doctor electronically prescribes a psychotropic medicine to a patient in India. The patient attempts to obtain it from an Indian online pharmacy.

Legal questions:

Is the medicine permitted in India?

Does the foreign doctor have relevant prescribing authority?

Does the prescription comply with Indian restrictions?

Does the pharmacy possess the necessary authority to dispense the medicine?

Legal position:

Electronic authentication alone does not establish legal authority to dispense a controlled medicine. The NDPS Act, Drugs and Cosmetics Act and applicable rules must be considered.

12. Proposed reforms for India

India could develop a more comprehensive legal framework for international electronic prescription recognition.

The following reforms would be significant.

A. International prescription recognition legislation

India could introduce specific statutory provisions establishing the conditions under which foreign electronic prescriptions may be recognised.

Such legislation should distinguish between:

Prescriptions issued in countries having reciprocal arrangements with India.

Prescriptions issued by internationally accredited hospitals.

Prescriptions issued by individually licensed foreign doctors.

Prescriptions involving controlled substances.

B. International doctor verification system

A central verification mechanism could enable Indian pharmacies to verify:

Foreign medical registration.

Professional qualifications.

Prescribing authority.

Licence validity.

Disciplinary restrictions.

C. Digital prescription authentication

India could establish internationally compatible electronic prescription authentication standards.

These should include secure electronic signatures, prescription identifiers, tamper detection and audit trails.

D. Reciprocal healthcare agreements

India could negotiate bilateral or multilateral arrangements with countries such as Australia, Japan, Germany, Singapore and the United Kingdom.

Such agreements could specify:

Recognised professional licensing authorities.

Minimum prescription information.

Electronic authentication standards.

Controlled-medicine exclusions.

Liability allocation.

Patient-data protection.

E. Centralised electronic prescription verification

A secure national verification mechanism could allow participating pharmacies to check the authenticity and dispensing status of foreign prescriptions.

F. Clear liability rules

Legislation should clarify the responsibility of the original doctor, receiving pharmacist, healthcare platform and regulatory authorities.

G. International patient protection

Patients should have accessible complaint mechanisms when prescriptions are wrongfully rejected, improperly dispensed or unlawfully disclosed.

13. Important legal questions for research and litigation

The following questions may form the basis of advanced biotechnology, healthcare and pharmaceutical law research:

Whether a foreign electronic prescription creates enforceable rights in the receiving jurisdiction.

Whether a digital prescription constitutes an exercise of medical practice within the patient's country.

Whether foreign medical registration is sufficient for cross-border prescribing.

Whether national regulators can reject electronically authenticated prescriptions.

Whether refusal to recognise foreign prescriptions violates international patient-mobility rights.

Whether pharmacists have an independent duty to verify foreign prescribing authority.

Whether electronic prescription authentication creates evidentiary presumptions.

Whether prescription databases can be shared internationally without additional patient consent.

Whether AI-generated prescriptions can receive cross-border recognition.

Whether a digital healthcare platform can be held liable for accepting fraudulent foreign prescriptions.

Whether a country can prohibit the dispensing of medicines lawfully prescribed in another country.

Whether reciprocal prescription recognition agreements should include mandatory dispute-resolution mechanisms.

14. Conclusion

Cross-Border Recognition of Electronic Prescriptions represents an important development in international healthcare law.

The legal framework must balance three competing interests:

Patient mobility: Patients should be able to continue their medical treatment when travelling internationally.

Professional accountability: Only appropriately authorised professionals should prescribe medicines.

Public health protection: Pharmacies must comply with the pharmaceutical and safety requirements of their own jurisdictions.

The European Union provides an important example through Directive 2011/24/EU and Implementing Directive 2012/52/EU.

The judgment in VIPA Kereskedelmi és Szolgáltató Kft. v. Hungary (Case C-222/18) demonstrates that recognition is conditional upon legally adequate prescription information and patient identification.

In India, the Information Technology Act, 2000, Telemedicine Practice Guidelines, 2020, Drugs and Cosmetics Act, 1940, Drugs Rules, 1945 and NDPS Act, 1985 provide important parts of the applicable legal framework. However, they do not collectively establish automatic recognition of prescriptions issued by foreign doctors.

The central legal principle is that recognition of an electronic prescription does not automatically confer prescribing authority, authorise the sale of a medicine or override the pharmaceutical laws of the receiving country.

A comprehensive international framework should therefore combine mutual recognition, digital authentication, professional licensing verification, pharmaceutical safety and patient-data protection.

15. Important case law and legislation reference table

Primary legal research sources

EU Directive 2011/24/EU – Article 11.

EU Implementing Directive 2012/52/EU.

CJEU judgment – VIPA, Case C-222/18.

India – Telemedicine Practice Guidelines.

CDSCO – Drugs Rules, 1945.

Priyanka Singh v. State of Maharashtra.

Deepa Sanjeev Pawaskar v. State of Maharashtra.

Research qualification: The first case is directly concerned with cross-border prescription recognition. The Indian judgments address related remote-prescribing, negligence and pharmaceutical compliance questions; they should not be cited as establishing an international prescription-recognition rule.